Western pharma firms lobby Trump administration to preserve China partnership opportunities

Western pharmaceutical companies are urging the Trump administration to permit continued collaborations with Chinese firms on promising drug candidates, despite a 2025 law that limits U.S. investment in Chinese technology.

The legislation threatens to curtail joint research and development efforts that many firms consider vital for advancing new therapies, especially in areas where Chinese partners have unique assets or patient populations.

An industry trade group is coordinating the lobbying effort, warning that a strict interpretation of the law could slow pipeline progress and reduce access to innovative treatments for patients worldwide.